Status:
UNKNOWN
Prasugrel in Severe COVID-19 Pneumonia
Lead Sponsor:
Azienda Ospedaliera Universitaria Integrata Verona
Collaborating Sponsors:
University of Milan
Conditions:
COVID19
Thrombosis
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
Inflammatory diseases favour the onset of venous thromboembolic events in hospitalized patients. Thromboprophylaxis with a fixed dose of heparin/low molecular weight heparin (LMWH) is recommended if c...
Detailed Description
Severe respiratory failure and multi-organ damage in coronavirus disease 2019 (COVID-19) patients have not a unitary pathophysiological interpretation. There is evidence of an association between the ...
Eligibility Criteria
Inclusion
- Covid-19 pneumonia
- Age over 18 years
- Willingness to express consent
Exclusion
- Active neoplasia or in maintenance therapy
- Pregnancy and breastfeeding
- Any absolute contraindication to the use of antiplatelet drugs
- Pathological bleeding in progress.
- Recent major bleeding at any location
- Need to use therapeutic doses of oral anticoagulants or heparins
- Need to use antiplatelet in combination for clinical indication
- Hypersensitivity to the active substance prasugrel or any of the excipients
- Clinical history of stroke or transient ischemic attack (TIA).
- Severe liver failure (Child-Pugh class C).
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2021
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT04445623
Start Date
July 1 2020
End Date
January 1 2021
Last Update
June 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Italy, 37126